Price
Target price
€0.28
€0.28
-10.390%
-0.032
-10.390%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Recce Pharmaceuticals Ltd. Stock
Heavy losses for Recce Pharmaceuticals Ltd. today as the stock fell by -€0.032 (-10.390%).
Pros and Cons of Recce Pharmaceuticals Ltd. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
News
Recce Pharmaceuticals Reports Positive Data From Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial of RECCE® 327
Highlights:
- Phase I/II rapid infusion clinical trial demonstrates efficacy on bacterial growth in dosed participants injected with RECCE® 327 (R327) at the highest tested dose of
Recce Pharmaceuticals Receives Ethics Approval to Centralise and Broaden RECCE® 327 Gel Clinical Trials across all Topical Bacterial Skin Infections
Highlights:
- Positions RECCE® 327 (R327) Gel as potential broad application topical therapeutic for all bacterial skin infections, formally referred to as complicated skin and
Further R&D Rebate Approved
SYDNEY Australia, 18 June 2024: Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of Synthetic Anti-infectives, is pleased to announce a